© 1996 American Heart Association, Inc.
Articles |
Comparison of the Effects of the Thrombin Inhibitor r-Hirudin in Four Animal Models of Neointima Formation After Arterial Injury
the Institute of Cardiovascular Research, Bayer AG, Wuppertal, Germany.
Correspondence to Dr Christoph Gerdes, Bayer AG, Institute of Cardiovascular Research, D-42096 Wuppertal, Germany.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Thrombin has been implicated as a contributing factor to restenosis after vessel reopening procedures. We compared the ability of the direct thrombin inhibitor recombinant (r-) hirudin to reduce neointimal growth in different animal models of arterial injury. Carotid arteries of rats, rabbits, and hypercholesterolemic minipigs were injured by withdrawal of an inflated balloon catheter. In addition, we used a double-lesion model in rabbits, which involved balloon angioplasty of a preexisting lesion induced by carotid denudation 4 weeks earlier. r-Hirudin was given in all four animal models as a short-term application (bolus of 1 mg/kg IV immediately before injury, followed by infusion of 1 mg · kg-1 · h -1 for 2 hours, and an injection of 6 mg/kg SC). Additionally, we investigated the effects of prolonged treatment (intravenous infusion for 3 and 14 days) in rats. Inhibition of thrombin was monitored by determination of activated partial thromboplastin time, and histomorphometric analysis of the arteries was performed after 2 (rats) or 4 (rabbits and minipigs) weeks. In rabbits, short-term r-hirudin treatment reduced neointimal area by 59% (single-injury model, P=.05) and 44% (double-injury model, P=.02). In rats and minipigs no inhibition of neointimal growth was observed after short-term r-hirudin application. A 3- or 14-day infusion of r-hirudin in rats, however, resulted in 25% (P=.007) and 27% (P=.003) reductions in neointimal area, respectively. In conclusion, there is considerable interspecies variation in the time frame of susceptibility for reduction of neointimal growth by inhibition of thrombin after arterial injury. These results demonstrate the importance of testing potential antirestenotic treatments in an array of different animal models.
Key Words: restenosis • animal models • arterial injury • thrombin • r-hirudin
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Restenosis is the major limiting factor to the long-term success of PTCA.1 2 Several mechanisms have been proposed to contribute to luminal renarrowing after the dilating procedure, which is very often accompanied by severe vessel wall injury.3 4 Initially, activation of platelets and the coagulation system induces deposition of platelets and fibrin at the angioplasty site. Subsequently, chemoattractants and mitogens induce migration and proliferation of SMCs.5 6 An additional increase in tissue volume is obtained by the production of extracellular matrix. Different adaptations of the vessel wall (ie, remodeling) have also been postulated, but to date the underlying mechanisms are only poorly understood.7 8
Besides the action of thrombin in the early thrombotic phase, its potential involvement in later stages of the restenotic process is also suggested by its direct chemoattractant and mitogenic effects on SMCs.9 10 11 12 These effects occur via a receptor-mediated pathway,13 and increased expression of the thrombin receptor has been demonstrated in human atherosclerotic tissue.14
Animal studies have confirmed the presence of early thrombin-dependent events immediately after balloon angioplasty of porcine carotid arteries by the reduction of fibrin and platelet deposition with the direct thrombin inhibitor r-hirudin.15 16 In a study of atherosclerotic rabbit arteries, short-term treatment with r-hirudin for 2 hours reduced restenosis 4 weeks after angioplasty.17 We compared the effects of r-hirudin in different animal models of arterial injury to identify variations among species, between models of single and double arterial injury, and between short- and long-term r-hirudin treatment.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Rat Experiments
Male Wistar rats (Charles River, Sulzfeld, Germany; body weight, 300 to 400 g) maintained on a normal rat chow diet were anesthetized by injection of pentobarbital (0.05 mg/kg IP; Nembutal, Sanofi). Whenever necessary, supplementary anesthesia was provided by inhalation of methoxyflurane (Penthrane, Abbott Laboratories). A midline ventral neck incision was made and the right external carotid artery exposed for arteriotomy. A 2F Fogarty embolectomy catheter (Baxter) was introduced into the common carotid artery to its origin at the aortic arch. The balloon was inflated with saline to distend the vessel wall and withdrawn three times with slight resistance to completely remove the endothelium. The external carotid artery was ligated and the neck incision closed with surgical sutures. After having received their respective r-hirudin or control treatment, the rats were allowed to recover until they were killed by an overdose of pentobarbital 2 weeks after injury.
Rabbit Experiments
Male New Zealand White rabbits (Interfauna, Huntingdon, England; body weight, 2.5 to 3.5 kg) maintained on a normal rabbit chow diet were anesthetized with ketamine (8 mg/kg IV; Ketavet, Parke-Davis) and xylazine (0.4 mg/kg IV; Rompun, Bayer). Additional anesthesia was achieved by administration of ketamine (35 mg/kg IM) and xylazine (4 mg/kg IM). The injury procedure was performed with a 3F Fogarty balloon catheter and was analogous to that in rats, resulting in denudation of the endothelial layer. In the single-injury experiments the rabbits were killed with an overdose of pentobarbital 4 weeks after the injury procedure. In the double-injury model, left carotid arteries underwent a second dilatation-induced injury 4 weeks after the initial one. For the second injury a 3.5-mm Gruntzig angioplasty catheter (ACS, Danimed) was introduced via the external carotid artery and inflated in the previously denuded area twice for 30 seconds each to 5 to 6 atm. Previous experiments have shown disruption of preexisting plaque and a restimulation of neointimal growth by this technique.18 The vessels were harvested 4 weeks after the second injury.
Minipig Experiments
Male Gottingen miniature pigs (Lars Ellegard, Dalmose, Denmark; body weight, 27 to 36 kg) were fed an atherogenic diet containing 1% cholesterol and 10% dried egg yolk starting 9 months before and continuing throughout the course of the experiment. Total plasma cholesterol levels were monitored enzymatically (Boehringer Mannheim kit). The minipigs were anesthetized with azaperone (8 mg/kg IM; Stresnil, Janssen) and metomidate (Hypnodil, Janssen; 10 mg/kg IP). Whenever necessary, supplementary metomidate was given intravenously. The minipigs received heparin (100 U/kg IV) for anticoagulation. The right common carotid artery was surgically exposed and opened by a distal 5-mm longitudinal incision. A 5F Fogarty balloon catheter was introduced proximally into the carotid artery, inflated with saline, and withdrawn five times under near-maximal distention of the arterial wall. Previous experiments revealed complete endothelial denudation and disruption of medial layers by this procedure. The catheter was removed, the incisions were closed by surgical sutures, and the animal was allowed to recover after finishing its respective r-hirudin or control treatment. Postoperative antibiotic protection was provided by penicillin (Tardomyocel, Bayer; 500 000 IU IM TID). Pigs received aspirin (500 mg/d PO) until the end of the experiment. Four weeks after injury the pigs were killed by exsanguination after captive bolt stunning. All experiments conformed to the German federal animal protection law and were approved by the legal district authority.
r-Hirudin Treatment
r-Hirudin (supplied by Rhein Biotech) was dissolved in sterile physiological saline. In the first experiment 14 rats received short-term treatment with r-hirudin, consisting of an intravenous bolus of 1 mg/kg immediately before injury, followed by an infusion of 1 mg · kg-1 · h -1 IV for 2 hours via the left jugular vein, and concluded by a single subcutaneous injection of 6 mg/kg 2 hours after injury. Seven control animals were administered saline via the same protocol. In the second experiment r-hirudin was delivered as a long-term treatment for 3 (n=10) or 14 (n=14) days by infusion of 1 mg · kg-1 · h -1 IV via osmotic pumps (Alzet 2ML2, Alza Corp). The pumps were implanted under the dorsal skin and connected to a flexible plastic tube that had been introduced into the left jugular vein. Ten control animals received saline infusions under the same protocol.
Rabbits were administered the short-term treatment only (1 mg/kg IV bolus, 1 mg · kg-1 · h-1 IV infusion for 2 hours, and 6 mg/kg SC injection), which was given to 10 animals in the single-injury experiment (control, n=10). In the double-injury experiment (n=7; control, n=24) the rabbits underwent r-hirudin treatment after the second dilatation-induced injury.
Minipigs (n=10; control, n=18) received the short-term r-hirudin treatment (1 mg/kg IV bolus, 1 mg · kg-1 · h -1 IV infusion for 2 hours, and 6 mg/kg SC injection) at the time of injury.
The level of thrombin inhibition was monitored by determination of the aPTT (Boehringer Mannheim aPTT kit) at different times during the r-hirudin treatment. To minimize stress in the rats induced by withdrawal of excess blood, sampling for aPTT determinations was done in a parallel group of 12 r-hirudin–treated rats.
Tissue Analysis
After the animals were killed the injured vessels were flushed in situ with buffered saline containing 0.7% (wt/vol) NaNO2 to achieve maximal vasodilation and standardize vessel wall tone. Carotid arteries were subsequently perfused with 10% (vol/vol) buffered formalin at 100 mm Hg pressure. After excision the injured vessels were divided into segments (1 segment per rat, 2 per rabbit, and 4 per minipig carotid artery), stored in 10% (vol/vol) formalin, and embedded in OCT medium for cryosectioning. Frozen sections were stained with resorcin-fuchsin, van Gieson's picrofuchsin, and hematoxylin.
Morphometric analysis was performed with a videomicroscope and a computerized image processing system (IMPAC). After the lumen boundary and internal and external elastic laminae for each section were manually traced, cross-sectional areas of lumen, neointima, media, and total vessel were calculated and the neointima to media ratio was derived. In previous experiments, specific segments with the most pronounced neointima formation had been identified for each species. These segments were selected for further evaluation by averaging the morphometric data from 5 sections in each segment. Vessels with occlusive thrombi were excluded from further analysis.
Statistics
All data are presented as mean±SEM. Statistical comparisons between groups were performed with unpaired t tests and data were rejected as not significantly different if P>.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Plasma Coagulation and Lipid Measurements
In all species examined, short-term r-hirudin treatment resulted in a nearly 2-fold to 4-fold prolongation of the aPTT (Fig 1
) for at least 4 hours. In rats given short-term r-hirudin, the maximal aPTT level was 44.2±1.4 seconds versus a baseline value of 15.5±1.3 seconds. In rats treated with r-hirudin for 3 days, aPTT on day 2 was elevated to 20.2±0.9 seconds from a baseline level of 10.7±0.5 seconds. Rats given r-hirudin for 14 days displayed an aPTT elongation on day 7 of 20.1±0.9 seconds and at sacrifice on day 14 of 20.3±1.0 seconds (baseline, 10.7±0.5 seconds).
|
In rabbits treated with r-hirudin, aPTT peaked at 95.3±9.4 seconds in the single-injury experiment and at 133.8±13.9 seconds in the double-injury experiment from baseline levels of 50.3±5.9 and 60.9±4.4 seconds, respectively.
In minipigs, short-term r-hirudin treatment produced a maximum aPTT elongation of 80.5±6.8 seconds from a baseline of 22.4±1.3 seconds. The atherogenic diet fed to the minipigs resulted in an increase of total plasma cholesterol from 
2 mmol/L (baseline) to 11.9±0.4 mmol/L (mean±SEM, n=20) within 4 weeks after the diet was started.
Occurrence of Thrombotic Occlusions
Occlusive thrombi in injured arteries were observed in rabbits and minipigs. In the rabbit single-injury experiment, 1 vessel from an r-hirudin–treated animal was occluded. In the rabbit double-injury experiment, no occlusions occurred in the r-hirudin–treated group, but 63% (15 of 24) of injured carotid arteries were occluded in the control group. In minipigs the thrombosis rate in r-hirudin–treated animals was 40% (4 of 10) and in control animals 56% (5 of 9).
Morphometry
Morphometric parameters are summarized in the Table. In rats short-term r-hirudin treatment did not significantly change the cross-sectional areas of any vessel compartment (Fig 2). However, a 3- or 14-day infusion of r-hirudin in rats resulted in reductions of 25% (P=.007) or 27% (P=.003), respectively, in neointimal area, which corresponded to significant reductions in the neointima to media ratio. A slight (18%) reduction in total vessel area was observed in rats treated with r-hirudin for 3 days after injury.
|
|
P<.01 vs control group.
In rabbits, short-term r-hirudin treatment reduced neointimal area by 59% (single injury, P=.05; Fig 3) and 44% (double-injury model, P=.02). In addition, a significant increase (47%) in luminal cross-sectional area was observed in r-hirudin–treated rabbits in the double-injury experiment.
|
In minipigs there were no significant changes in morphometric parameters after short-term treatment with r-hirudin, although a trend toward a reduction in lumen size and an increase in neointima area was seen (Fig 4).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A variety of pharmacological interventions have been used to reduce the rate of restenosis after PTCA. Clinical trials have yielded either negative or conflicting results, despite the inhibitory effects on myointimal growth that have been observed after arterial injury in one or two animal (mostly rodent) models.19 20 21 One large-scale trial demonstrated a long-term reduction in clinical events with use of the human monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor (c7E3); however, there was no angiographic evidence of reduced restenosis.22 Although this study was conducted in a population of high-risk patients, it emphasizes the role of platelet activation in the formation of restenotic lesions. Among its effects on other cells and coagulation, thrombin is the most potent platelet activator that is generated at the angioplasty site in the vessel wall.23
Mechanisms of Thrombin in Vascular Injury
Activation of platelets by thrombin is accomplished via proteolytic cleavage of the membrane-bound thrombin receptor.13 This receptor has also been identified on SMCs, where its stimulation results in cellular proliferation and migration,9 10 11 12 and on monocytes, which respond to thrombin stimulation with chemotaxis.24 Increased expression of the thrombin receptor has been demonstrated in human atherosclerotic tissue14 and in lesions formed after experimental arterial injury.25 These multiple functions of thrombin suggest its potential involvement in several phases of the restenotic process after vessel reopening procedures.26
Choice of r-Hirudin Treatment Regimen
The direct thrombin inhibitor r-hirudin has proved to be highly effective in preventing platelet and fibrin deposition in stented porcine coronary arteries and after balloon injury of porcine carotid arteries.16 23 In an atherosclerotic rabbit balloon angioplasty model, r-hirudin reduced restenosis when infused for only 2 hours.17 We took a similar approach but gave an additional subcutaneous injection to achieve an 2-fold aPTT elongation for at least 4 hours.
Animal Models
To our knowledge this is the first published report on the long-term effects of r-hirudin in a rat arterial injury model. After short-term treatment had not shown an effect on morphometric parameters with respect to vessel response, we decided to treat the rats with a continuous infusion of r-hirudin for 3 or 14 days. Both treatment groups displayed a similar reduction in neointimal area (25% and 27%, respectively), indicating that there is a time frame for neointima reduction by thrombin inhibition of 3 days after injury. Although highly significant, the size of the effect is only moderate and might be explained by a slightly lower aPTT prolongation than the 2-fold increase that we had aimed for.
In the rabbit experiments, our results confirm the findings of other groups with r-hirudin and the irreversible thrombin inhibitor D-Phe-Ala-Pro-Arg chloromethyl ketone.17 27 Sarembock et al17 were the first to find angiographic and histomorphometric evidence of reduced stenosis by r-hirudin in an atherosclerotic rabbit femoral artery angioplasty model. In that study, however, histomorphometric parameters were expressed as percent lumen stenosis only. In our experiments neointimal area was reduced by r-hirudin in both the single- and the double-injury model in rabbits. However, an increase in vessel lumen area was observed in the double-lesion model only. This finding is of particular interest because preexisting atherosclerotic plaque in experimental arterial injury is an important feature when experimental data are extrapolated to the clinical situation.19 20
Another characteristic of the double-lesion model is the high rate of thrombotic occlusion compared with only 1 case in the single-injury experiment. This observation corresponds to different types of injury, with endothelial denudation only in the single-lesion model versus disruption of the plaque and media in the double-lesion model. Treatment with r-hirudin eliminated thrombosis in the double-injury experiment, compared with a 63% reocclusion rate in the placebo-treated group.
The findings in our rat and rabbit models suggest interspecies differences in the time of susceptibility to thrombin inhibition after arterial injury. The narrowest time frame obviously exists in rabbits, in which treatment for a few hours resulted in the most marked reduction in neointimal area. This may suggest that thrombin acts primarily in the acute thrombotic phase after injury. There is evidence, however, that thrombin generation persists in deendothelialized rabbit aortic walls for as long as 10 days after injury.28
In rats susceptibility to thrombin inhibition lasts 3 days. The lack of further reduction in neointimal area by extending r-hirudin treatment for >3 days may suggest that the role of thrombin in this species is limited to the acute phase of thrombocyte deposition. As has been observed in thrombocytopenic rats,29 a reduction in platelet deposition results in less release of mediators (probably platelet-derived growth factor30 ) that influence the migration but not proliferation of SMCs. However, with regard to the absence of an intimal layer in normal rat arteries and the importance of SMC migration, the rat model must be considered with caution as a model for human restenosis.
The differences in responsiveness to r-hirudin treatment between rats and rabbits may be partly explained by differential activity of the coagulation system or by variable thrombogenicity of the injured vessel wall surface. Fingerle et al29 described a persistent thrombogenic subendothelium in rats 48 hours after injury, whereas data for rabbits suggest that 8 to 10 hours after injury the exposed subendothelium becomes inactivated and unresponsive to platelets.31
Our results in the minipig model did not reveal any positive effect of short-term r-hirudin treatment on morphometric parameters. We cannot exclude the possibility that any inhibitory effects of r-hirudin might have been masked by the heparin plus aspirin treatment given to all animals. However, there was a trend toward a reduction of thrombotic occlusion (probably due to deep medial injury) from 56% in the control group to 40% in the r-hirudin–treated group. In porcine arterial injury models, contradictory effects of r-hirudin treatment have been published. In a carotid artery model of deep balloon injury, Webster et al32 observed a significant reduction in fibrinogen deposition after a 2-week infusion of r-hirudin. The reduction in intimal area and number of proliferating cells, however, did not achieve statistical significance. In a minipig coronary stent model, Unterberg et al33 recently found a significant reduction in mean intimal thickness that was comparable with that achieved with two intravenous boluses alone and continued with subcutaneous treatment for 2 weeks. We did not evaluate such continued treatment, but the data of Unterberg et al33 suggest positive effects of r-hirudin therapy, with anticoagulation levels comparable to those achieved in our study. However, their model involved injury of minipig coronary arteries with oversized stents, which may not be exactly comparable to our carotid artery balloon injury procedure. This is important with regard to the predictive value of pig models of restenosis, which have been considered superior to various small-animal models,19 20 34 because of their anatomic and pathophysiological correlates to the human situation as well as their susceptibility to atherosclerosis. For example, in both porcine models and the clinical situation, angioplasty characteristically results in deep injury with disruption of subendothelial layers.35 Indeed, many agents that have demonstrated antiproliferative effects in rodent models later proved to have negative effects in both pigs and humans.36 37 38 39
Clinical Correlations
A recent clinical trial40 investigated the effects of adjunctive treatment with r-hirudin in PTCA patients. At 7 months neither clinical nor angiographic end points differed significantly from those in heparin-treated control subjects. However, the incidence of early clinical events was significantly reduced when r-hirudin was given intravenously on the first day followed by subcutaneous treatment for another 3 days after PTCA. Another trial compared the use of bivalirudin (Hirulog), another direct thrombin inhibitor, with heparin during PTCA.41 Bivalirudin did not improve clinical outcome except for a reduction of acute ischemic complications in a subgroup of patients with postinfarction angina.
The observation of improvement in early clinical events by thrombin inhibition during PTCA raises the issue of potentially beneficial effects of prolonged thrombin inactivation after angioplasty. Restenosis development in humans usually takes several months compared with assessment periods of only a few weeks in current animal models. Thus, long-term improvements in clinical outcome might require prolonged thrombin inactivation.
The problem of prolonged thrombin inhibition, however, is its interference with the blood coagulation system. Although neither r-hirudin nor bivalirudin increased the rate of bleeding complications compared with heparin-treated control groups in clinical trials of post-PTCA restenosis,40 41 r-hirudin treatment has revealed the risk of bleeding complications in other studies,42 43 thus indicating the need for closely monitoring blood coagulation during treatment with thrombin inhibitors.
In conclusion, the interspecies variations observed with identical r-hirudin treatments recommend the use of a combination of animal models before initiating large-scale clinical trials of potential antirestenotic treatments. A definitive answer to the question of how much of the observed effects of r-hirudin can be attributed to inhibition of receptor activation rather than of blood coagulation presumably awaits the discovery of potent, selective receptor antagonist compounds.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
The authors gratefully acknowledge Beate Kranz, Wolfgang Roggan, and Manfred Schumacher for their expert technical assistance and Paul Rounding for helpful scientific discussions.
Received December 5, 1995;
revision received March 20, 1996;
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ellis SG, Muller DWM. Arterial injury and the enigma of coronary restenosis. J Am Coll Cardiol. 1992;19:275-277.[Medline] [Order article via Infotrieve]
2. Ludbrook PA. Coronary restenosis: its mechanisms and modification. Coronary Artery Dis. 1993;4:225-228.
3. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.[Abstract]
4. Davies MG, Hagen P-O. Pathobiology of intimal hyperplasia. Br J Surg. 1994;81:1254-1269.[Medline] [Order article via Infotrieve]
5. Liu MW, Berk BC. Restenosis following coronary balloon angioplasty. Trends Cardiovasc Med. 1991;1:107-111.
6. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
7.
Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
8.
Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 1995;76:996-1002.
9.
Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb. 1994;14:254-260.
10. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
11. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol. 1995;37:C1195-C1201.
12. Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Physiol. 1995;37:C1141-C1147.
13. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.[Medline] [Order article via Infotrieve]
14. Nelken NA, Soifer SJ, O'Keefe J, Vu T-KH, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
15.
Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
16. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, Munz DL, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol. 1993;21:249-254.[Abstract]
17.
Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
18. Faber V, Grutzmann R, Wohlfeil S, Zaiss S, Gerdes C. Balloon dilatation of pre-injured rabbit carotid arteries increases myointimal plaque formation: a valuable tool to study restenosis? Atherosclerosis. 1994;109:7. Abstract.
19. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.[Abstract]
20. Jackson CL. Animal models of restenosis. Trends Cardiovasc Med. 1994;4:122-130.
21. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approach to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 1993;46:18-52 and 1993;46:249-262.[Medline] [Order article via Infotrieve]
22. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.[Medline] [Order article via Infotrieve]
23.
Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
24.
Bar-Shavit R, Kahn A, Wilner GD. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 1983;220:728-731.
25.
Wilcox HN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong CZ, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038.
26. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
27. Walters TK, Gorog DA, Wood RFM. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J Vasc Res. 1994;31:173-177.[Medline] [Order article via Infotrieve]
28. Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol. 1989;135:499-508.[Abstract]
29.
Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989;86:8412-8416.
30.
Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
31.
Groves HM, Kinlough-Rathbone RL, Mustard JF. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis. 1986;6:189-195.
32. Webster MWI, Chesebro JH, Grill DE, Badimon JJ, Badimon L, Fuster V. The thrombotic and proliferative response to angioplasty in pigs after deep arterial injury: effect of intravenous thrombin inhibition with hirudin. Circulation. 1991;84(suppl II):II-580. Abstract.
33. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol. 1995;26:1747-1754.[Abstract]
34.
Ferrell M, Fuster V, Gold HK, Chesebro JH. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85:1630-1631.
35.
Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985;57:105-112.
36.
MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? results of the MERCATOR study: a multicenter, randomized double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
37. Lam JYT, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after ballon injury of porcine carotid arteries. Circulation. 1992;85:154-157.
38.
Lovastatin restenosis trial study group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
39. Schneider JE, Santoian EC, Gravanis MB, Cipolla G, Anderberg K, King SB. Lovastatin fails to limit smooth muscle cell proliferation in normolipemic and hyperlipemic swine in an overstretch balloon injury model of restenosis. J Am Coll Cardiol. 1992;19:163A. Abstract.
40.
Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Van Dijk R, Van Den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW for the HELVETICA investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
41.
Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B for the hirulog angioplasty study investigators. Treatment with Bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
42.
Antman EM. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI)-9a trial. Circulation. 1994;90:1624-1630.
43.
Topol E, Califf R, Vandewerf F, Ardissino D, Armstrong P, Aylward P, Barbash G, Bates E, Beatt K, Betriu A, Chesebro J, Col J, Ellis S, Emanuelsson H, Fuster V, Gibler W, Gore J, Guerci A, Hochman J, Holmes D, Kleiman N, Morris D, Neuhaus K, Ohman M, Pfisterer M, Phillips H, Rutsch W, Simes J, Simoons M, Vahanian A, Weaver D, White H. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
This article has been cited by other articles:
 |
|
 |
|
  N. Fukai, R. D. Kenagy, L. Chen, L. Gao, G. Daum, and A. W. Clowes Syndecan-1: An Inhibitor of Arterial Smooth Muscle Cell Growth and Intimal Hyperplasia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1356 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bea, J. Kreuzer, M. Preusch, S. Schaab, B. Isermann, M. E. Rosenfeld, H. Katus, and E. Blessing Melagatran Reduces Advanced Atherosclerotic Lesion Size and May Promote Plaque Stability in Apolipoprotein E- Deficient Mice Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2787 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. de Waard, E. K. Arkenbout, P. Carmeliet, V. Lindner, and H. Pannekoek Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 1978 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andrade-Gordon, C. K. Derian, B. E. Maryanoff, H.-C. Zhang, M. F. Addo, W.-m. Cheung, B. P. Damiano, M. R. D'Andrea, A. L. Darrow, L. de Garavilla, et al. Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 34 - 42. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Patterson, G. A. Stouffer, N. Madamanchi, and M. S. Runge New Tricks for Old Dogs : Nonthrombotic Effects of Thrombin in Vessel Wall Biology Circ. Res., May 25, 2001; 88(10): 987 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Erlich, E. M. Boyle, J. Labriola, J. C. Kovacich, R. A. Santucci, C. Fearns, E. N. Morgan, W. Yun, T. Luther, O. Kojikawa, et al. Inhibition of the Tissue Factor-Thrombin Pathway Limits Infarct Size after Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation Am. J. Pathol., December 1, 2000; 157(6): 1849 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-m. Cheung, M. R. D’Andrea, P. Andrade-Gordon, and B. P. Damiano Altered Vascular Injury Responses in Mice Deficient in Protease-Activated Receptor-1 Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 3014 - 3024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takada, H. Tanaka, T. Yamada, O. Ito, M. Kogushi, M. Yanagimachi, T. Kawamura, T. Musha, F. Yoshida, M. Ito, et al. Antibody to Thrombin Receptor Inhibits Neointimal Smooth Muscle Cell Accumulation Without Causing Inhibition of Platelet Aggregation or Altering Hemostatic Parameters After Angioplasty in Rat Circ. Res., May 19, 1998; 82(9): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Courtman, S. M. Schwartz, and C. E. Hart Sequential Injury of the Rabbit Abdominal Aorta Induces Intramural Coagulation and Luminal Narrowing Independent of Intimal Mass : Extrinsic Pathway Inhibition Eliminates Luminal Narrowing Circ. Res., May 19, 1998; 82(9): 996 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gallo, A. Padurean, V. Toschi, J. Bichler, J. T. Fallon, J. H. Chesebro, V. Fuster, and J. J. Badimon Prolonged Thrombin Inhibition Reduces Restenosis After Balloon Angioplasty in Porcine Coronary Arteries Circulation, February 17, 1998; 97(6): 581 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Nichols, D. A. Bellinger, R. L. Reddick, G. G. Koch, J. L. Sigman, G. Erickson, T. du Laney, T. Johnson, M. S. Read, and T. R. Griggs von Willebrand Factor Does Not Influence Atherogenesis in Arteries Subjected to Altered Shear Stress Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 323 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Capron, J. Jarnet, D. Heudes, D. Joseph-Monrose, and P. Bruneval Repeated Balloon Injury of Rat Aorta : A Model of Neointima With Attenuated Inhibition by Heparin Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1649 - 1656. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||